Patient Engagement/Monitoring

Lupus Research Alliance Appoints EVP of Affiliate Lupus Therapeutics

The Lupus Research Alliance (LRA) is pleased to announce the appointment of Stacie J. Bell, PhD as Executive Vice President to lead Lupus Therapeutics, the organization’s clinical research affiliate.

An accomplished research scientist and organizational leader, Dr. Bell comes to Lupus Therapeutics with more than 25 years of experience in discovery research, clinical development, and patient engagement in the biopharmaceutical and nonprofit arenas.

Most recently she formed and served as CEO and President of the Global Nutrition Project, a nonprofit organization intended to empower humanity to transform the health of people and the planet by using innovative technologies, fostering collaboration with diverse partners, and leveraging big data.

Prior to that, Dr. Bell served as Chief Scientific and Medical Officer leading the Research & Medical Affairs department at the National Psoriasis Foundation. In this capacity she elevated research efforts, strengthened partnerships to support the community, worked with health policy makers, and initiated the first organizational clinical study. She also was part of the working group for the Accelerated Medicine Partnership program for the second phase, AMP-AIM, a federal program that the Lupus Research Alliance has been involved with since its inception. This effort involves stakeholders from industry, academics, and government agencies to accelerate the scientific understanding of disease mechanism, treatment innovation, and personalized medicine.

“We are very pleased to welcome Dr. Bell to the Lupus Research Alliance family,” commented Albert T. Roy, LRA President and CEO and former Executive Director of Lupus Therapeutics. “She brings exactly the right blend of academic, pharmaceutical, and non-profit experience to guide Lupus Therapeutics to new heights. With her deep knowledge of evolving science and technology, as well as her ability to galvanize an impassioned patient community, Dr. Bell possesses all the skills to propel our vision – addressing urgent unmet medical needs and one day, eradicating lupus.”

“Throughout my career, I have worked to advance treatment options and ultimately improve patient care particularly, in immunology and rheumatology,” noted Dr. Bell. “I am excited about working with the lupus community to bring together diverse stakeholders, drive patient engagement, and accelerate clinical research for this disease which requires many individualized treatments. I am honored to further the mission of Lupus Therapeutics which has had impressive success since its inception. 

Dr. Bell began her career as a Graduate Research Associate in the Department of Biochemistry at Vanderbilt University School of Medicine in Nashville, TN where she earned her PhD in Biochemistry. She graduated summa cum laude with a BS in Chemistry from University of North Dakota.

Visit AITechPark for cutting-edge Tech Trends around AI, ML, Cybersecurity, along with AITech News, and timely updates from industry professionals!

Related posts

Sharecare wins 17 Fall 2021 Digital Health Awards

PR Newswire

Sutter Health Uses Docent for its Virtual Patient Navigation Platform

Business Wire

The Academy and Nuance Partner to Launch The AI Collaborative

PR Newswire